GenScript adjusted net profit more than triples to US$62.5 million in FY26 H1; revenue rises 27.3% to US$404.2 million

• GenScript posted first-half revenue of about US$404.2 million, up 27.3% year over year on a comparable basis.
• Adjusted net profit climbed 203.3% to about US$62.5 million.
• Life Science Group revenue rose 28.8% to about US$319 million; adjusted operating profit jumped 102.8% to about US$94 million.
• AI-enabled drug discovery business doubled year over year for a third straight half-year; Gene-to-Protein contributed about 66% of segment revenue.
• ProBio revenue increased 34.2% to about US$61.1 million; adjusted operating loss narrowed 22.5% to US$24.3 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GenScript Biotech Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608181000PR_NEWS_USPR_____NY28577) on August 18, 2026, and is solely responsible for the information contained therein.